Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verastem (GB:0LOV)
LSE:0LOV
Holding GB:0LOV?
Track your performance easily
0LOV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.14 - $13.94
Previous Close$2.4
Volume100.00
Average Volume (3M)2.55K
Market Cap
$99.00M
Enterprise Value$57.49M
Total Cash (Recent Filing)$83.37M
Total Debt (Recent Filing)$41.86M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Oct 31, 2024EPS Estimate
-$0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding40,243,745
10 Day Avg. Volume632
30 Day Avg. Volume2,548
Standard Deviation0.26
R-Squared0.00259
Alpha0.00440
Financial Highlights & Ratios
Price to Book (P/B)5.25
Price to Sales (P/S)9.90
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.75
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$11.67Price Target Upside387.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Verastem News
Bulls Say, Bears Say
Bulls Say
FDA ApprovalFDA approval and a product launch for avutometinib plus defactinib in KRAS-mutant low grade serous ovarian cancer could happen next year, which would be the first commercial revenue for Verastem Inc.
Financial PerformanceReported operating expenses were lower than expected, with reported cash of $83 million as of June 30, 2024, expected to sustain company operations through the potential approval of avutometinib plus defactinib in the first half of 2025.
Market OpportunityThe opportunity for avutometinib plus defactinib not only in low grade serous ovarian cancer but also in non-small cell lung cancer and pancreatic ductal adenocarcinoma represents upside potential to current estimates.
Bears Say
Clinical Trial ResultsDisappointment is expressed regarding the lower overall response rate in the RAMP 201 study compared to previously reported data.
Price TargetThe 12-month price target is adjusted to $7.00 per share from $17.50 due to equity dilution.
Safety ConcernsConcerns around potential safety issues seen for avutometinib and defactinib in the RAMP 205 study are noted.
---
0LOV FAQ
What was Verastem’s price range in the past 12 months?
Verastem lowest share price was $2.14 and its highest was $13.94 in the past 12 months.
What is Verastem’s market cap?
Currently, no data Available
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is Oct 31, 2024 which is in 61 days.
How were Verastem’s earnings last quarter?
Verastem released its earnings results on Aug 08, 2024. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.962 by $0.652.
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem does not currently pay dividends.
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -$0.75.
How many shares outstanding does Verastem have?
Verastem has 40,243,744 shares outstanding.
What happened to Verastem’s price movement after its last earnings report?
Verastem reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.962. Following the earnings report the stock price went up 4.194%.
Which hedge fund is a major shareholder of Verastem?
Among the largest hedge funds holding Verastem’s share is Viking Global Investors LP. It holds Verastem’s shares valued at N/A.
---
Verastem Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.67 (387.27% Upside)
$11.67 (387.27% Upside)
Blogger Sentiment
Bullish
GB:0LOV Sentiment 100%
Sector Average 68%
Sector Average 68%
Insider Transactions
Sold Shares
Worth $13.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.94%
12-Months-Change
Fundamentals
Return on Equity
-109.97%
Trailing 12-Months
Asset Growth
-44.85%
Trailing 12-Months
Company Description
Verastem
Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
---
0LOV Stock 12 Month Forecast
Average Price Target
$11.67
▲(387.27% Upside)
Technical Analysis
Verastem
―
Pieris Pharmaceuticals
―
Madrigal Pharmaceuticals
―
Voyager Therapeutics
―
Kura Oncology
―
Best Analysts Covering 0LOV
1 Year
1 Year Success Rate
8/22 ratings generated profit
1 Year Average Return
-14.25%
reiterated a buy rating 20 days ago
Copying Sean Lee CFA's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -14.25% per trade.
---